Pharmaceutical

FlackTek™ Technology Preserves Terpenes in Cannabis Concentrates

LANDRUM, S.C., Aug. 14, 2024 /PRNewswire/ -- In a new study titled "Preserving Terpenes in Cannabis Concentrates During Solvent Purging: The…

1 year ago

Veridix AI, part of Emmes Group, Announces New Protocol Digitization Capabilities

Protocol digitization extracts structured data elements from unstructured textAutomates database study builds, reducing build timelines by up to 30%Deployed within…

1 year ago

Petauri™ Acquires Medical Communications Agencies in Major Expansion

Rapidly growing pharmaceutical services platform adds four world-class agencies from the Brightly Network NASHVILLE, Tenn., Aug. 14, 2024 /PRNewswire/ --…

1 year ago

Scientific Industries to Host Second Quarter 2024 Financial Results Investor Call on August 15, 2024

Investor Call to be held at 11:00 AM Eastern Time BOHEMIA, NY / ACCESSWIRE / August 14, 2024 / Scientific…

1 year ago

ADMA Biologics Announces Partial Paydown of Revolving Credit Facility

Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties Lowers…

1 year ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage…

1 year ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC…

1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14,…

1 year ago

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s diseaseROCHESTER,…

1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout…

1 year ago